COVID-19: combining antiviral and anti-inflammatory treatments

COVID-19: combining antiviral and anti-inflammatory treatments

Vol 20 April 2020 | Long Chen, Jing Xiong, Lei Bao, *Yuan Shi
Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information. The center grants free access to its research in PubMed Central and other repositories. At Guangdong Second Provincial General Hospital, infection control observers monitor negative pressure isolation wards, ensuring proper infection control measures. Observers monitor staff during procedures and provide support when errors occur, such as when a nurse's glove was ripped. The observer helped the nurse properly remove the glove and arrange for medical observation. The observing system is a proactive tool for preventing nosocomial infections, and the hospital plans to use AI image recognition to improve its effectiveness. Convalescent plasma has been used as a potential treatment for SARS-CoV-2 infections. Studies show that it can reduce mortality and hospital stay in patients with severe infections. However, no specific treatment has been proven effective for SARS-CoV-2. The WHO recommends infection prevention, case detection, and supportive care for COVID-19. Convalescent plasma from recovered patients may be a viable treatment option, though more research is needed. Combining antiviral and anti-inflammatory treatments may be effective for severe COVID-19 cases. Baricitinib, a JAK inhibitor, is a potential candidate due to its anti-inflammatory properties and high affinity for AAK1. It is approved for use in rheumatoid arthritis and myelofibrosis. Clinical trials show it has a favorable safety profile. Other AI-predicted NAK inhibitors are also being explored.Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information. The center grants free access to its research in PubMed Central and other repositories. At Guangdong Second Provincial General Hospital, infection control observers monitor negative pressure isolation wards, ensuring proper infection control measures. Observers monitor staff during procedures and provide support when errors occur, such as when a nurse's glove was ripped. The observer helped the nurse properly remove the glove and arrange for medical observation. The observing system is a proactive tool for preventing nosocomial infections, and the hospital plans to use AI image recognition to improve its effectiveness. Convalescent plasma has been used as a potential treatment for SARS-CoV-2 infections. Studies show that it can reduce mortality and hospital stay in patients with severe infections. However, no specific treatment has been proven effective for SARS-CoV-2. The WHO recommends infection prevention, case detection, and supportive care for COVID-19. Convalescent plasma from recovered patients may be a viable treatment option, though more research is needed. Combining antiviral and anti-inflammatory treatments may be effective for severe COVID-19 cases. Baricitinib, a JAK inhibitor, is a potential candidate due to its anti-inflammatory properties and high affinity for AAK1. It is approved for use in rheumatoid arthritis and myelofibrosis. Clinical trials show it has a favorable safety profile. Other AI-predicted NAK inhibitors are also being explored.
Reach us at info@study.space
[slides and audio] Convalescent plasma as a potential therapy for COVID-19